AI drug discovery has moved from platform pitches to clinical tests. One recent sign: in October 2026, Iambic Therapeutics raised $150 million in a Nasdaq IPO, saying in its filing …   Read More

With Science Foundries, launched today, the R&D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on …   Read More

Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: …   Read More

Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with. …   Read More

Inside the growing bet that AI can find the patients pharma's failed trials missed... Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million …   Read More